New whipworm drug could beat standard treatment in one dose
NCT ID NCT07258173
First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This study compares a single dose of emodepside to a single dose of albendazole (the usual treatment) in 100 adolescents and adults infected with a type of whipworm. The goal is to see which drug cures more infections and reduces egg counts. Participants provide stool samples before and 14-21 days after treatment to measure success.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- emodepside
- What this could lead to
- If successful, this could offer a new single-dose treatment for whipworm infections that is more effective than the current standard.
- What could go wrong
- This is a small Phase 2 trial with only 100 participants, so results may not apply broadly. The drug may not prove superior or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Nov 2026
An estimate. Start dates often move.
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
12 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged 12 years and above. * Written informed consent signed by participant and, in the case of minors, parents/caregivers. * Agree to comply with study procedures, including provision of two stool samples at the beginning (screening) and at follow-up assessment 14-21 days after treatment. * Having at least two slides of the quadruple Kato-Katz thick smears positive for Trichuris incognita and infection intensities of at least 48 eggs per gram (EPG). * Willing to be examined by a study physician prior to treatment. Exclusion Criteria: * Presence or signs of major systemic illnesses, e.g. body temperature ≥ 38 °C, severe anemia (Hb below 80g/l) upon initial clinical assessment etc. * History of severe acute or unmanaged severe chronic disease (i.e., condition is not as therapeutically controlled as necessary). * Positive malaria rapid diagnostic test (RDT) and temperature ≥ 38 °C. * Abnormal liver and renal function assessed by biochemical blood-based analyses. * Recent use of anthelmintic drugs (in the 4 weeks before treatment). * Known allergy to study medications and formulations (i.e. albendazole and emodepside). * Prescribed or taking medication with known contraindication to or interaction with study drugs. * Participating in other clinical trials during the study period. * Pregnancy or breastfeeding.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Trichuris are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.